News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
75,569 Results
Type
Article (967)
Company Profile (11)
Press Release (74591)
Section
Business (21250)
Career Advice (129)
Deals (8320)
Drug Development (6711)
Employer Resources (2)
FDA (1324)
Job Trends (1561)
News (38125)
Policy (2765)
Tag
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (1)
2026 Pharm Country Premier (1)
Academia (88)
Allergies (2)
Alliances (5919)
ALS (8)
Alzheimer's disease (138)
Antibody-drug conjugate (ADC) (3)
Approvals (1335)
Artificial intelligence (6)
Automation (2)
Bankruptcy (84)
Best Places to Work (1392)
Biosimilars (9)
Biotechnology (7)
Bladder cancer (3)
Brain cancer (2)
Breast cancer (19)
Cancer (196)
Cardiovascular disease (7)
Career advice (110)
CAR-T (7)
Cell therapy (27)
Cervical cancer (1)
Clinical research (5685)
Collaboration (55)
Compensation (23)
COVID-19 (92)
C-suite (23)
Cystic fibrosis (10)
Data (205)
Depression (3)
Diabetes (19)
Diagnostics (690)
Digital health (3)
Diversity, equity & inclusion (1)
Drug discovery (6)
Drug pricing (2)
Duchenne muscular dystrophy (3)
Earnings (7454)
Employer branding (1)
Employer resources (2)
Events (10323)
Executive appointments (95)
FDA (1436)
Featured Employer (4)
Frontotemporal dementia (1)
Funding (81)
Gene editing (3)
Gene therapy (9)
GLP-1 (23)
Government (192)
Guidances (3)
Healthcare (1995)
Immunology and inflammation (4)
Indications (2)
Infectious disease (102)
Inflammatory bowel disease (15)
Influenza (5)
Intellectual property (10)
Interviews (23)
IPO (4852)
Job creations (208)
Job search strategy (93)
Layoffs (8)
Legal (900)
Liver cancer (3)
Lung cancer (35)
Lymphoma (10)
Manufacturing (16)
MASH (6)
Medical device (1824)
Medtech (1824)
Mergers & acquisitions (3721)
Metabolic disorders (41)
Multiple sclerosis (6)
NASH (1)
Neurodegenerative disease (2)
Neuroscience (183)
NextGen: Class of 2025 (905)
Non-profit (163)
Northern California (243)
Obesity (17)
Opinion (2)
Ovarian cancer (6)
Pain (9)
Pancreatic cancer (17)
Parkinson's disease (19)
Partnered (3)
Patents (32)
Patient recruitment (11)
Peanut (2)
People (6564)
Pharmacy benefit managers (1)
Phase I (1761)
Phase II (2635)
Phase III (1859)
Pipeline (141)
Policy (1)
Postmarket research (146)
Preclinical (678)
Press Release (1)
Prostate cancer (7)
Psychedelics (1)
Radiopharmaceuticals (44)
Rare diseases (27)
Real estate (525)
Recruiting (1)
Regulatory (1838)
Reports (5)
Research institute (136)
Resumes & cover letters (15)
RSV (3)
Schizophrenia (10)
Series A (6)
Series B (7)
Sickle cell disease (8)
Southern California (284)
Spinal muscular atrophy (2)
Startups (496)
State (1)
Stomach cancer (1)
Supply chain (5)
United States (3012)
Vaccines (23)
Weight loss (2)
Date
Today (4)
Last 7 days (45)
Last 30 days (276)
Last 365 days (4000)
2025 (1044)
2024 (4453)
2023 (5504)
2022 (6721)
2021 (7851)
2020 (7553)
2019 (5271)
2018 (4083)
2017 (3918)
2016 (3233)
2015 (4529)
2014 (3094)
2013 (2533)
2012 (2710)
2011 (2362)
2010 (2113)
Location
Africa (20)
Alabama (2)
Arizona (23)
Arkansas (1)
Asia (3704)
Australia (469)
California (688)
Canada (144)
China (29)
Colorado (21)
Connecticut (45)
Delaware (12)
Europe (5208)
Florida (146)
Georgia (23)
Idaho (7)
Illinois (57)
India (1)
Indiana (55)
Japan (10)
Kansas (19)
Kentucky (1)
Maine (35)
Maryland (96)
Massachusetts (449)
Michigan (60)
Minnesota (42)
Mississippi (2)
Missouri (11)
Montana (2)
Nebraska (3)
Nevada (23)
New Hampshire (9)
New Jersey (265)
New Mexico (2)
New York (283)
North Carolina (184)
Northern California (243)
Ohio (29)
Oregon (2)
Pennsylvania (194)
Rhode Island (3)
South America (64)
South Carolina (6)
Southern California (284)
Tennessee (23)
Texas (160)
Utah (40)
Virginia (23)
Washington D.C. (1)
Washington State (52)
West Virginia (1)
Wisconsin (11)
75,569 Results for "cerevasc llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CereVasc Announces First Patient Randomized to eShunt® System Treatment in STRIDE Pivotal Trial
February 25, 2025
·
3 min read
Press Releases
CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in Argentina
February 14, 2025
·
3 min read
Press Releases
CereVasc Announces First Enrollment in STRIDE Clinical Trial of the eShunt® System for Normal Pressure Hydrocephalus
January 14, 2025
·
3 min read
Press Releases
CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure Hydrocephalus
February 5, 2025
·
4 min read
Press Releases
CereVasc to Present at the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
·
1 min read
Genetown
CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephalus
CereVasc, Inc. announced today that it has received approval from the US Food and Drug Administration (FDA) to initiate its “Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus” (STRIDE trial).
May 7, 2024
·
2 min read
Genetown
CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced it has successfully completed the initial closing of a $70 Million Series B financing.
May 13, 2024
·
2 min read
Genetown
CereVasc’s eShunt® System Study Data Presented at the ABC WIN Seminar
CereVasc, Inc. announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat communicating hydrocephalus, was presented at the ABC WIN Seminar in Val d’Isere.
January 23, 2024
·
2 min read
Press Releases
CereVasc Announces Appointments of New Directors
July 16, 2024
·
3 min read
Genetown
CereVasc’s eShunt™ System to be Presented at the International Stroke Conference by Dr. Pedro Lylyk
CereVasc, Inc. announced that Dr. Pedro Lylyk, Director General of ENERI, will deliver a symposium presentation entitled, “Endovascular Shunting for Hydrocephalus After Subarachnoid Hemorrhage and Other Applications,” at the International Stroke Conference in Phoenix, Arizona on Wednesday, February 7th.
February 7, 2024
·
2 min read
1 of 7,557
Next
